Nicole Murphy Biography and Net Worth

Head of Pharmaceutical Operations and Technology of Biogen

Nicole Murphy is Executive Vice President, Pharmaceutical Operations and Technology of Biogen and joined the Executive Committee in 2022. Ms. Murphy joined Biogen in 2015 and has held senior executive positions, including most recently as Senior Vice President, Head of Global Manufacturing & Technical Operations (GMTO). In 2017, Ms. Murphy played a critical role during the successful spin-off of Biogen’s hemophilia franchise, as the Vice President and Head of Technical Operations of Bioverativ and prior to the spin-off was the General Manager and Head of Cambridge Site Operations at Biogen. Ms. Murphy has extensive experience in leading Supply Chain, Quality, Process Development, Manufacturing and Engineering functions. Prior to joining Biogen Ms. Murphy spent over 15 years at Amgen.

Ms. Murphy holds an MS in Chemical Engineering, an MBA from Rensselaer Polytechnic Institute, and a BS in Engineering from the University of Massachusetts at Amherst. Ms. Murphy serves on a variety of industry councils and committees.

What is Nicole Murphy's net worth?: The estimated net worth of Nicole Murphy is at least $3.83 million as of February 12th, 2026. Ms. Murphy owns 19,611 shares of Biogen stock worth more than $3,826,694 as of February 24th. This net worth evaluation does not reflect any other investments that Ms. Murphy may own. Additionally, Ms. Murphy receives a salary of $1,450,000.00 as Head of Pharmaceutical Operations and Technology at Biogen. Learn More about Nicole Murphy's net worth.
How old is Nicole Murphy?: Ms. Murphy is currently 51 years old. There are 7 older executives and no younger executives at Biogen. The oldest executive at Biogen is Ms. Susan H. Alexander Esq., Executive VP & Chief Legal Officer, who is 67 years old. Learn More on Nicole Murphy's age.
What is Nicole Murphy's salary?: As the Head of Pharmaceutical Operations and Technology of Biogen Inc., Ms. Murphy earns $1,450,000.00 per year. There are 4 executives that earn more than Ms. Murphy. The highest earning executive at Biogen is Mr. Christopher A. Viehbacher, President, CEO & Director, who commands a salary of $4,070,000.00 per year. Learn More on Nicole Murphy's salary.
How do I contact Nicole Murphy?: The corporate mailing address for Ms. Murphy and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. Biogen can also be reached via phone at (617) 679-2000 and via email at [email protected]. Learn More on Nicole Murphy's contact information.
Has Nicole Murphy been buying or selling shares of Biogen?: Over the course of the past ninety days, Nicole Murphy has bought $585.09 of Biogen stock. Most recently, on Thursday, February 12th, Nicole Murphy bought 3 shares of Biogen stock. The stock was acquired at an average cost of $195.03 per share, with a total value of $585.09. Following the completion of the transaction, the insider now directly owns 19,611 shares of the company's stock, valued at $3,824,733.33. Learn More on Nicole Murphy's trading history.
Who are Biogen's active insiders?: Biogen's insider roster includes Susan Alexander (EVP), Rachid Izzar (Insider), Nicole Murphy (Head of Pharmaceutical Operations and Technology), Brian Posner (Director), Eric Rowinsky (Director), Alfred Sandrock (insider), Stephen Sherwin (Director), Stephen Sherwin (Director), Stephen Sherwin (Director), Priya Singhal (Insider), and Michel Vounatsos (CEO). Learn More on Biogen's active insiders.
Are insiders buying or selling shares of Biogen?: During the last twelve months, Biogen insiders bought shares 1 times. They purchased a total of 3 shares worth more than $585.09. During the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 14,908 shares worth more than $2,348,989.75. The most recent insider tranaction occured on February, 12th when insider Nicole Murphy bought 3 shares worth more than $585.09. Insiders at Biogen own 0.2% of the company. Learn More about insider trades at Biogen.
Information on this page was last updated on 2/12/2026.

Nicole Murphy Insider Trading History at Biogen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/12/2026	Buy	3	$195.03	$585.09	19,611

Nicole Murphy Buying and Selling Activity at Biogen

Biogen Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $195.13

$194.43

$198.72

50 Day Range

MA: $180.90

$164.42

$201.18

2 Week Range

Now: $195.13

$110.04

$202.41

Volume

716,039 shs

Average Volume

1,541,893 shs

Market Capitalization

$28.64 billion

P/E Ratio

22.15

Dividend Yield

N/A

Beta

0.16

Nicole Murphy Biography and Net Worth

What is Nicole Murphy's net worth?

How old is Nicole Murphy?

What is Nicole Murphy's salary?

How do I contact Nicole Murphy?

Has Nicole Murphy been buying or selling shares of Biogen?

Who are Biogen's active insiders?

Are insiders buying or selling shares of Biogen?